Idiopathic hypersomnia (IH) is a difficult disease state to identify, compounded by suboptimal clinician understanding. Data shows that clinicians lack the ability to identify IH based on clinical presentation and changes in quality of life (QoL), with correct diagnosis often taking a decade or more. Additionally, data shows that clinicians lack knowledge regarding diagnostic process for IH. This has a tremendous impact on patients’ abilities to function, and often prevents patients and their families from living a full life. Timely and accurate diagnosis must be achieved if patients are to improve, as the current timeline to diagnosis of up to 10-15 years is not reasonable for patients who are suffering.
In this CMEO BriefCase activity, join expert faculty Dr. Thorpy and Dr. Morse for a discussion on best practices to integrate appropriate assessments and tools to facilitate early diagnosis of IH.
Integrate appropriate assessments and tools to facilitate early diagnosis of IH.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Thorpy reports the following financial relationships:
Advisory Board/Consultant: Alkermes; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Ltd.; Takeda Pharmaceuticals U.S.A., Inc.; and XWPharma Ltd.
Dr. Morse reports the following financial relationships:
Advisory Board: Alkermes; Avadel; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation
Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.
Employment: DAMM Good Sleep, LLC (CEO)
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).